Department of Veterans Affairs Awarded a Contract to ADVANCED ACCELERATOR APPLICATIONS USA INC for $5,367,276.64

Summary of Award

The JSON data obtained from usaspending.gov details a contract awarded by the U.S. Department of Veterans Affairs to Advanced Accelerator Applications USA Inc. This contract, identified as a delivery order under the award ID "36C26225F0024," is focused on the delivery of pharmaceutical products, specifically Pluvicto and Lutathera, and is valued at $5,367,276.64. The contract period starts on November 1, 2024, and concludes on October 31, 2025. These pharmaceutical products are likely to be used for medical treatments within the VA healthcare system, possibly for specialized therapies given their specific nature.

Advanced Accelerator Applications USA Inc., the contract recipient, is located in New York, NY, as indicated by their listed address at 350 5th Ave Ste 6902, NY 10118. The company is noted as being part of several business categories, indicating a diverse operational structure. It is characterized as a "Corporate Entity Not Tax Exempt" and is identified as foreign-owned but incorporated within the United States. The classification of the company as a "Manufacturer of Goods" within the "Small Business" category further denotes its capacity within the pharmaceutical manufacturing industry, specifically under the North American Industry Classification System (NAICS) code 325412, which relates to Pharmaceutical Preparation Manufacturing.

The Department of Veterans Affairs, both the awarding and funding agency, plays a crucial role, given its responsibility in providing healthcare services to veterans. The New York State-based company won the contract via full and open competition, a method signifying that the procurement process allowed eligible bidders to compete for the award. The chosen solicitation procedure, described with the acronym MAFO (Multiple Award Fair Opportunity), indicates a competitive environment though the advanced nature of the products—Pluvicto and Lutathera—suggests they might have had limited sources considering the unique nature of targeted therapies. Navigating the specifics of the contract's transactions, we observe two significant entries. The initial transaction, dated October 28, 2024, aligns with the contract signing date and records the total transaction amount of $5,367,276.64. This reflects the full value of the contractual obligation, likely covering the complete intended supply of the specified pharmaceutical products. A subsequent transaction, dated April 10, 2025, notes a modification (categorized as "P00001") leading to a negative transaction amounting to -$496,636.35. This reduction could hint at a contract adjustment, potentially due to changes in delivery requirements, amendments in service scope, or adjustments based on updated negotiation between the parties. Such financial amendments are not uncommon in large-scale government contracts where initial estimates require recalibration post-award. Regarding the place of performance—Millburn, Essex County, NJ—it is possible that the services, or at least a component of them, are rendered in proximity to the main healthcare facilities, enabling efficient distribution or utilization of the pharmaceutical products by the VA. Despite being foreign-owned, Advanced Accelerator Applications USA Inc. conducts business as a U.S.-incorporated entity, thus fulfilling necessary governmental and regulatory conditions. Their alignment within categorized business structures and industry levels underscores the strategic collaboration between governmental needs and specialized private sector capabilities. From a broader perspective, the contract’s activity mirrors the overarching objectives of the Department of Veterans Affairs to leverage biopharmaceutical innovations, reflecting a commitment to enhancing veteran care through specialized medications such as Pluvicto and Lutathera. These drugs, often utilized in treating specific cancer types, are critical to veterans requiring such targeted therapy, suggesting the VA’s ongoing push to integrate advanced medical solutions for its beneficiaries. In conclusion, the outlined contract encapsulates a well-structured transaction between the federal government and a niche pharmaceutical company, aligning both public obligations and private sector expertise to meet vital health care objectives. This venture aligns with the Department's continued focus on evolving health care paradigms while ensuring fiscal responsibility and precise expenditure given the dynamics noted within the transaction history.